lunes, 18 de enero de 2021

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas | FDA

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas | FDA

No hay comentarios:

Publicar un comentario